Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
HIV Self-testing Skyrockets Among Transgender Individuals in New Study
February 17th 2021Compared with being offered standard testing services, offers of initial and repeat self-testing led to a 3.5-fold greater uptake of testing for HIV among transgender individuals in a new study out of England and Wales.
Researchers Call for Earlier Monitoring of Cardiac Function Among High-risk Patients
February 15th 2021An analysis of 30-year data on participants from the Augusta Heart study shows that Black individuals begin to exhibit potential signs of congestive heart failure earlier than their White counterparts.
Recognize Dermatologists for Their Role in HIV, AIDS Fight, Review Says
February 10th 2021This year marks the 40th anniversary of the initial appearance in the United States of what we now know to be HIV and AIDS, first manifesting as Pneumocystis carinii pneumonia and Kaposi’s sarcoma among gay men and intravenous drug users.
Entresto Is Top HFrEF Treatment Recommendation in Updated ACC Guidelines
January 28th 2021Treatment optimization for heart failure with reduced ejection fraction is the focus of the American College of Cardiology’s 2021 update to its 2017 Expert Consensus Decision Pathway on managing patients with the condition.
Likely Determinants of Successful TKI Treatment Stoppage Identified in CML
January 16th 2021Tyrosine kinase inhibitor (TKI) therapy enables patients with chronic myeloid leukemia (CML) to reach life expectancies equivalent to the general population and treatment-free remission, but quality of life can deteriorate with treatment.
Jardiance 1 Step Closer to FDA Approval for Use in Heart Failure
January 11th 2021The FDA today accepted Boehringer Ingelheim and Eli Lilly’s supplemental New Drug Application for Jardiance (empagliflozin), the sodium glucose co-transporter 2 inhibitor being investigated for use in patients with heart failure.